The endothelium of blood vessels plays a crucial role in the regulation of blood flow by controlling mechanical functions of underlying vascular smooth muscle. The regulation by the endothelium of vascular smooth muscle relaxation and contraction is mainly achieved via the release of vasoactive substances upon stimulation with neurohumoural substances and physical stimuli. Nitric oxide (NO) and prostaglandin I2 (prostacyclin, PGI2) are representative endothelium-derived chemicals that exhibit powerful blood vessel relaxation. NO action involves activation of soluble guanylyl cyclase and PGI2 action is initiated by the stimulation of a cell-surface receptor (IP receptor, IPR) that is coupled with Gs-protein-adenylyl cyclase cascade. Many studies on the mechanisms by which NO and PGI2 elicit blood vessel relaxation have highlighted a role of the large conductance, Ca 2+ -activated K + (MaxiK, BKCa) channel in smooth muscle as their common downstream effector. Furthermore, their molecular mechanisms have been unravelled to include new routes different from the conventionally approved intracellular pathways. MaxiK channel might also serve as a target for endotheliumderived hyperpolarizing factor (EDHF), the non-NO, non-PGI2 endothelium-derived relaxing factor in some blood vessels. In this brief article, we review how MaxiK channel serves as an endothelium-vascular smooth muscle transducer to communicate the chemical signals generated in the endothelium to control blood vessel mechanical functions and discuss their molecular mechanisms.
Introduction
The endothelium, which surrounds blood vessels in their inner surfaces, plays an elementary role in the short-and long-term regulation of peripheral vascular resistance to determine blood pressure and thus blood flow. This is mainly achieved by the release of vasoactive substances from the endothelium, which consequently alters the electrical and mechanical activities of the underlying blood vessel smooth muscle. Endothelium-derived vasoactive substances include both relaxants and constrictors. NO (Bian and Murad, 2003; Furchgott, 1995; Ignarro, 1989; Moncada et al., 1991) and prostaglandin I2 (prostacyclin, PGI2) (Coleman et al., 1994; Moncada et al., 1976; Narumiya et al., 1999; Wise and Jones, 1996) are representative endothelium-derived relaxants. The endothelium also releases non-NO, non-PGI2 substance(s) that is/are tentatively termed as endothelium-derived hyperpolarizing factor(s) (EDHF(s)) (Busse et al., 2002; Garland et al., 1995; McGuire et al., 2001; Mombouli and Vanhoutte, 1997; Quilley and McGiff, 2000; Suzuki et al., 1992; Suzuki et al., 1998; Suzuki, 2003; Taylor and Weston, 1988; Triggle et al., 2003) though its/their chemical identity is/are not yet established. The extent of the contribution of these endothelium-derived blood vessel relaxants varies depending on the species, vascular tissues and stimulations applied to the endothelium.
However, the actions of these endothelium-derived relaxing substances in many cases commonly involve membrane hyperpolarization of vascular smooth muscle, and plasma membrane K + channels serve as key molecules to produce the membrane electrical events (Triggle et al., 2003; Waldron and Cole, 1999) (Fig. 1 ). K + channel subclasses contributing to the action of each endothelium-derived relaxant also
show diversity according to the species and vascular smooth muscle. In this regard, at least four subclasses are identified as the responsible K + channel molecules: the large conductance, Ca 2+ -activated K + (MaxiK, BK) channel, ATP-sensitive K + (KATP) channel, voltage-gated K + (Kv) channel (Beech, 1997; Nelson and Quayle, 1995; Standen and Quayle, 1998; Waldron and Cole, 1999) , and inward rectifier K + (Kir) channels (Edwards et al., 1998; Savage et al., 2003) 1 . Among these K + channel subclasses, MaxiK channel (Calderone, 2002; Knaus et al., 1994; Orio et al., 2002; Schubert and Nelson, 2001; Tanaka et al., 2004a; Toro et al., 1998; Wu, 2003) has been recently reviewed highlighting the critical role of its modulatory β subunits in cell function (Orio et al., 2002; Tanaka et al., 2004a) . However, MaxiK channel role in blood vessel relaxations mediated via endothelium-derived chemical factors has not been reviewed in detail. In this brief article, we particularly review vascular smooth muscle MaxiK channel as a key signaling molecule in mediating the blood vessel mechanical changes in response to endothelium-derived relaxants and discuss new molecular mechanisms emerging from recent studies. The roles for non-MaxiK-type of K + (Kv, KATP, Kir) channels in endothelium-dependent vascular relaxations are addressed in other review articles (Busse et al., 2002; Triggle et al., 1 EDHF-mediated blood vessel relaxation may involve the activation of apamin-sensitive small conductance Ca 2+ -activated K + (SK) channels. K + outflow through endothelial SK (likely SK3) channel has been proposed as an EDHF factor activating smooth muscle Kir channel to promote muscle hyperpolarization and relaxation (Edwards et al., 1998) . Recent evidence indicates that SK3 is expressed in endothelial cells but not in vascular smooth muscle (Burnham et al., 2002; Taylor et al., 2003). 2003; Waldron and Cole, 1999) .
General properties of vascular smooth muscle MaxiK channel
MaxiK channel is ubiquitously distributed among mammalian tissues and its expression level is particularly high in smooth muscles including vascular smooth muscle Toro et al., 1998) . A typical example of vascular smooth MaxiK channel recorded in a native cell is illustrated in Fig. 2A . The physiological significance of this ion channel remained, however, unravelled for a long time. Thanks to the combination of physiological and pharmacological approaches together with molecular and gene targeting technologies, the physiological relevance of MaxiK channel is universally agreed upon as a smooth muscle key ]i), which subsequently triggers the production of relaxant substances: nitric oxide (NO), prostaglandin I2 (prostacyclin, PGI2) and endothelium-derived hyperpolarizing factor (EDHF). For EDHF-mediated responses, the increase in endothelial [Ca 2+ ]i is also a crucial step (Busse et al., 2002) . Three chemical substances diffuse to reach the underlying vascular SMC and produce muscle relaxation partly through the activation of vascular smooth muscle K + channels. The activation of K + channels induce membrane hyperpolarization (MHP), which limits Ca 2+ entry through voltage-gated L-type Ca 2+ channel leading to the decrease in vascular smooth muscle [Ca 2+ ]i and muscle relaxation. The relaxant action of NO is chiefly mediated through activation of soluble type of guanylyl cyclase (sGC) and that of PGI2 is initiated through binding to the PGI2-specific receptor (IPR) that is coupled to Gs. Possible molecular mechanisms by which PGI2 and NO activate MaxiK channel (IPR-K channel system, NO-K channel system) are described in text.
element to control its electrical and mechanical activities. Since both intracellular Ca 2+ ([Ca 2+ ]i) and membrane voltage are fundamental determinants of MaxiK channel activity, this ion channel in vascular smooth muscle serves as a rheostat to finely tune membrane potential and intracellular Ca 2+ concentrations, and consequently blood vessel mechanical activities: the activation of MaxiK channel leads to smooth muscle membrane hyperpolarization and relaxation, whereas its inhibition leads to depolarization and contraction (Fig. 1) . This view is supported by pharmaco-mechanical evidence that suppression of MaxiK activity with its specific inhibitor, iberiotoxin (IbTx) (Galvez et al., 1990; Wallner et al., 1995) , induces blood vessel constriction (Brayden and Nelson, 1992; , which is quiescent in its absence;
and by experiments showing that vasoconstrictions induce MaxiK channel inhibition (Alioua et al., 2002) . In addition, the activity of MaxiK channel can be governed through direct and indirect mechanisms by a number of endogenous vasoactive substances Toro and Scornik, 1991) . The mechanisms by which vasoactive substances trigger the MaxiK channel currents and channel putative topology. A: MaxiK channel currents recorded in the smooth muscle cell isolated from guinea-pig aorta. MaxiK channel was recorded in inside-out patch configuration. In this case, patch membrane contains two channels. The solution contained equal K + concentrations at both sides of the membrane; thus, the zero current level at 0 mV. B: MaxiK channel is formed by two dissimilar membrane subunits: the pore-forming α-subunit and the regulatory β-subunit. The α-subunit is constructed with seven transmembrane regions (S0-S6) and a long COOH terminus with four hydrophobic segments (S7-S10). S4 is an intrinsic voltage-sensor, which is the main generator of gating currents demonstrating that MaxiK channel belongs to the Kv channel superfamily. The loop between S5-S6 is the pore (K + conducting route) of this channel, which is a target for iberiotoxin (IbTx), charybdotoxin and tetraethylammonium (TEA). β-Subunits including β1-subunit has two transmembrane regions and both NH2 and COOH terminals are oriented toward the cytoplasm.
actions of MaxiK channel have been explored at a molecular level revealing phosphorylation/ dephosphorylation of the channel protein as a key mechanism (Alioua et al., 1998; Alioua et al., 2002) . The molecular characteristics of MaxiK channel are addressed in detail in other review articles (Knaus et al., 1994; Orio et al., 2002; Tanaka et al., 2004a; Toro et al., 1998) , and thus, this article just outlines its main features.
MaxiK channel pore-forming α-subunit
MaxiK channel is composed by at least two distinct integral membrane subunits: the poreforming (ion-conducting) α-subunit (KCNMA1) and a regulatory β-subunit (KCNMB1-4) (Knaus et al., 1994; Toro et al., 1998) (Fig. 2B) . The α-subunit is the minimal molecular component for MaxiK channel activity and a functional MaxiK channel can be formed with four α-subunits. (Stefani et al., 1997) . However, MaxiK channel α-subunit has a distinguishable topological feature since it contains an additional seventh transmembrane region (S0) leading to an exoplasmic NH2 terminus . The S0 domain together with the exoplasmic NH2 terminal are indispensable for β-subunit modulation of this channel . Recently, two MaxiK channel α-subunit (mSlo1) deleted mice (Slo -/-mice) were constructed and their phenotype changes were examined (Meredith et al., 2004; Sausbier et al., 2004 functions, Slo -/-mice exhibits enhanced contractions in its urinary bladder and a marked elevation of urination frequency, which indicates that dysfunction of this channel leads to overactive bladder and urinary incontinence (Meredith et al., 2004) .
MaxiK channel β-subunit and its determinant role in smooth muscle mechanical activity MaxiK channel β-subunits are structurally distinct from other Kv channel β-subunits and key molecular constituents to determine tissue-specific channel functions and MaxiK channel diversity (Toro et al., 1998) . MaxiK channel β-subunit contains two transmembrane domains connected by an extracellular large loop, and is supposed to be associated with α-subunit in a 1:1 ratio. Among four different isoforms (β1-4 or KCNMB1-4) that have been identified as MaxiK channel β-subunit in mammals, the expression of β1-subunit is particularly high in smooth muscles including vascular smooth muscle (Jiang et al., 1999) . The most relevant role for
MaxiK channel β1-subunit is to enhance channel sensitivities to Ca 2+ and voltage (McManus et al., 1995; Meera et al., 1996; Tanaka et al., 1997) . β1-subunit makes MaxiK channel a target for a curative medicine, dehydrosoyasaponin I (DHS-I) (McManus et al., 1995; Tanaka et al., 1997) .
The actions of estradiol (17β-estradiol) on blood vessel smooth muscle might include its interaction with MaxiK channel β1-subunit (Valverde et al., 1999) . Functional roles for MaxiK channel β1-subunit in blood vessel mechanical activity has been revealed with β1-subunit-deleted mice (β1 -/-) (Brenner et al., 2000; Plüger et al., 2000) .
Cerebral artery from β1 -/-mice exhibits more potent myogenic tone in response to a pressure elevation (Brenner et al., 2000) and its aorta generates greater contraction to noradrenaline and KCl (Plüger et al., 2000) . The most important phenotypic changes caused by β1 ablation are: elevation of mean arterial blood pressure and hypertrophy of the heart muscle (Brenner et al., 2000) . The role for MaxiK channel β1 subunit in the maintenance of blood pressure is further supported by recent studies to show that the expression level of β1 subunit is down-regulated in cerebral arteries from angiotensin-induced (Amberg et al., 2003) and genetic (Amberg and Santana, 2003) hypertensive rats. In a genetic epidemiological study carried out in Spain, a single-nucleotide substitution (G352A) in the β1 gene (KCNMB1), corresponding to an E65K mutation, was identified (Fernández-Fernández et al., 2004) . MaxiK-β1(E65K) channels shows an increased Ca 2+ sensitivity, and might provide a more efficient negative-feedback system to blood vessel mechanical functions to prevent diastolic hypertension (Fernández-Fernández et al., 2004) . In summary, MaxiK channel β1-subunit is an essential molecular component which confers the ability to regulate blood vessel smooth muscle tone on this Ca 2+ -sensitive K + channel in physiological conditions.
Enhancement of MaxiK channel activity by endothelium-derived relaxant substances
Major chemical relaxant substances that are released from the endothelium upon its stimulation are: NO, PGI2 and EDHF. The chemical identity of EDHF is, however, not yet conclusively established. MaxiK channel role is significant in the blood vessel relaxations induced by NO and PGI2. The contribution of MaxiK channel may also be important in EDHFmediated relaxations in some blood vessels. In the following sections, we describe how vascular smooth muscle MaxiK channel is activated by these substances addressing their molecular mechanisms.
Nitric oxide (NO)
NO (Bian and Murad, 2003; Furchgott, 1995; Ignarro, 1989; Moncada et al., 1991) is the major blood vessel relaxant that is released from the endothelium. This powerful relaxant is released when the endothelium is stimulated with neurohumoural substances such as acetylcholine or with biophysical membrane deformation such as fluid shear stress (Triggle et al., 2003; Waldron and Cole, 1999) . NO is also provided to blood vessel smooth muscle via wellknown angina pectoris therapeutic drugs, nitroglycerin (NTG) and sodium nitroprusside (SNP). MaxiK channel roles in NO-mediated blood vessel relaxation have been highlighted by pharmaco-mechanical and electrophysiological studies with various kinds of blood vessels from different species as listed in Table 1 . NO action has been investigated using two toxin i n h i b i t o r s , I b T x a n d c h a r y b d o t o x i n ( C h T x ) , a n d / o r l o w e r c o n c e n t r a t i o n s o f tetraethylammonium (TEA, 1-2 mM). Of these inhibitors, IbTx is the best pharmacological tool to determine the significance of MaxiK channel role since its Kd value is very small (≈1 nM) and it does not affect other subclasses of K + channels (Wallner et al., 1995) . Although not listed in 2) When the chemicals are released from the endothelium upon stimulation with vasoactive substances such as acetylcholine (ACh), they are described like NO ACh , PGI2 ACh , EDHF ACh . ACh: acetylcholine; AA: arachidonic acid; MeCh; methacholine; BK; bradykinin; SIN-1: 3-(4-morpholinyl)-sydnonimine; SNP: sodium nitroprusside; SNAP: S-nitroso-N-acetyl-DLpenicillamine; NOR3:
3) MS: mechanical tension recording with vascular beds; PCS: patch clamp study with isolated cells; MPR: membrane potential recording with microelectrode.
4) The concentrations of inhibitors are shown as superscripts; IbTx: iberiotoxin; ChTx: charybdotoxin; TEA: tetraethylammonium.
5) Only the first author is shown. See details in reference section. Table 1 , non-MaxiK class of K + channels also play a role in NO-induced blood vessel relaxation:
for example, KATP channel in pial arteries (Armstead, 1996) and Kv channel in pulmonary arteries (Yuan et al., 1996; Zhao et al., 1997) . Regional (vascular bed-specific) differences in MaxiK channel role remains to be established. However, the role of MaxiK channel in NO-mediated vascular responses might be more pronounced in small arteries like cerebral and coronary arteries.
If NO-induced blood vessel relaxation includes MaxiK channel activation, NO should elicit membrane hyperpolarization of vascular smooth muscle through activation of this ion channel. In this regard, SNP causes membrane hyperpolarization in rat coronary artery, which is diminished by IbTx (Wellman et al., 1996) . Furthermore, NO and/or NO donors (e.g., SNP, SIN-1, NONOate) activate MaxiK channel in human (Bychkov et al., 1998) and bovine (Li et al., 1997b; coronary arteries, rabbit cerebral artery (Robertson et al., 1993) and aorta (Bolotina et al., 1994) , and in rat cerebral , mesenteric (Carrier et al., 1997; Mistry and Garland, 1998) arteries and renal arteriole (Sun et al., 1998) (Table 1) . These pharmaco-mechanical and electrophysiological lines of evidence support a significant role of MaxiK channel as a central downstream effector in NO-induced blood vessel relaxation.
There is general consensus that NO elevates cGMP levels in blood vessel smooth muscle through activation of soluble type of guanylyl cyclase (sGC) (Ignarro and Kadowitz, 1985; Ignarro, 1989) . As a consequence, the activity of a cGMP-dependent protein kinase (PKG) is enhanced causing phosphorylation of various intracellular proteins and vascular relaxation (Waldman and Murad, 1987) . Provided that NO-induced vascular relaxation depends on a cGMP-PKG signaling cascade, MaxiK channel can be a potential target for PKG in NO-induced blood vessel relaxation ( Fig. 3 (1) ). Alternatively, mechanisms independent of PKG might also account for the blood vessel relaxation mediated through NO-MaxiK channel cascade. In this regard, two mechanisms have been proposed so far, and they are: direct channel activation by N O ( F i g . 3 ( 2 ) ) ( B o l o t i n a e t a l . , 1 9 9 4 ) a n d i n h i b i t i o n o f t h e f o r m a t i o n o f 2 0 -hydroxyeicosatetraenoic acid (20-HETE) by NO ( Fig. 3 (3) ) Sun et al., 1998; Sun et al., 2000) . On the other hand, non-MaxiK-mediated mechanisms also underlie PKGmediated blood vessel relaxation like: (1) activation of the plasmalemmal Ca 2+ extrusion pump (Yoshida et al., 1991) ; (2) stimulation of Ca 2+ -ATPase activity to produce enhanced loading of Ca 2+ into intracellular Ca 2+ stores (Andriantsitohaina et al., 1995; Khan et al., 1998) ; (3) inhibition of agonist-stimulated Ca 2+ release from sarcoplasmic reticulum (Khan et al., 1998; Meisheri et al., 1986) ; and (4) decrease in the sensitivity of contractile elements to Ca 2+ (Yanagisawa et al., 1989) . In the following paragraphs, we address the molecular mechanisms by which MaxiK channel triggers NO-induced blood vessel relaxation (Fig. 3 ).
1) Activation of MaxiK channel by PKG through channel phosphorylation
Activation by PKG of vascular smooth muscle MaxiK channel was first evidenced independently by two groups (Robertson et al., 1993; Taniguchi et al., 1993) . They demonstrated in smooth muscle cells isolated from rabbit cerebral (Robertson et al., 1993) and dog coronary (Taniguchi et al., 1993) arteries that PKG added directly to the intracellular surface of inside-out patches increased MaxiK channel open probability (Po) in the presence of ATP and cGMP. This was also demonstrated in other arteries including rat coronary artery (Wellman et al., 1996) . Two mechanisms have been proposed: direct phosphorylation by PKG of MaxiK channel protein itself leading to channel activation, and activation of protein phosphatase 2A by PKG, which in turn causes dephosphorylation and activation of MaxiK channel (Zhou et al., 1996) . The former mechanism (direct channel phosphorylation) may be preferentially supported because: (1) purified MaxiK channels and native membranes derived from tracheal smooth muscle show the [γ-32 P]ATP-derived 32 P incorporation by PKG into the MaxiK channel corresponding bands (Alioua et al., 1995) ; and (2) the pore-forming MaxiK channel α-subunit contains one strong consensus sequence (serine-1072) for PKG phosphorylation in its C-terminal region (Toro et al., 1998) . The mechanism of direct channel phosphorylation of MaxiK channel by PKG and its consequential activation has been supported using expressed channels (Alioua et al., 1998) where: (1) the MaxiK channel α-subunit (hslo) coexpressed with PKG-Iα was activated by a permeant cGMP analog, 8-bromo-cGMP when it was applied to the external side of the channel;
(2) 8-bromo-cGMP-augmented membrane currents flowing through MaxiK channel α-subunit were reduced to control levels by treatment with alkaline phosphatase; (3) the open probability of MaxiK channel α-subunit was increased by recombinant PKG-Iα (Fig. 4) ; (4) MaxiK channel α-subunit was directly phosphorylated both in in vitro and in vivo conditions. Up to date, the PKG phosphorylation site(s) have not been conclusively determined. In this regard, two different results have been reported using cloned MaxiK channel α-subunit (Fukao et al., 1999; Nara et al., 2000) . In a study with HEK293 cell expressing MaxiK channel α-subunit cloned from canine colon (cSlo1), stimulatory effects of PKG and SNP are abolished by a point mutation of serine-1072 with alanine (the only optimal consensus sequence for PKG phosphorylation) (Fukao et al., 1999) . On the other hand, another mutagenesis study employing Xenopus oocyte expressing hSlo1 channel suggests a role of serine-855 as a PKG phosphorylation residue (Nara et al., 2000) . However, in the latter study, mutation of serine-855 in hSlo channel alone does not abolish the MaxiK channel-PKG stimulatory coupling. This coupling is abolished by the double mutation of serine-855 with serine-869, the cAMP-dependent protein kinase phosphorylation (PKA) site on the α-subunit (Nara et al., 2000) . Both studies favour the view that direct phosphorylation of MaxiK channel α-subunit increases channel activity, and thus, account in part for the molecular mechanisms responsible for NO-induced activation of this channel and vascular relaxation. However, a more conclusive answer independent of the differences in expression system needs to be drawn to account for the molecular mechanism that underlies MaxiK channel-PKG stimulatory coupling in native vascular smooth muscle cells.
2) Direct activation of MaxiK channel by NO
The concept of direct activation of vascular smooth muscle MaxiK channel by NO itself ( Fig. 3 (2) ) was first proposed by Bolotina et al. (1994) . To explore the possibility that NO directly affects the native MaxiK channel to increase its Po through a cGMP-PKG independent pathway, the authors employed cell-free membrane (excised) patches from rabbit aortic smooth muscle cells (Bolotina et al., 1994) . NO (applied as gas, 0.2-10 µM) rapidly increased MaxiK channel Po in both inside-out and out-side out membrane patches without affecting single channel conductance. An increase in MaxiK channel Po was also elicited when the inside-out membrane patch was exposed to the perfusate containing acetylcholine-produced NO generated in the aortic endothelium. The view that NO directly activates MaxiK channel independently of cGMP-PKG cascade was supported by the fact that the solution facing the channel internal side did not contain exogenous cGMP, Mg 2+ and ATP (Bolotina et al., 1994) . Blood vessel relaxant response to NO partly reflects this mechanism since NO-induced, sGC inhibitor-resistant relaxant component is prevented by ChTx. The molecular mechanisms by which NO directly activates vascular smooth MaxiK channel are not completely clarified. Since NO-elicited activation of MaxiK channel is prevented by N-ethylmaleimide (NEM), a chemical modification of sulphhydryl (-SH) group present on the channel or closely associated component might be involved in the mechanism (Bolotina et al., 1994) . MaxiK channel in rat small resistance arteries (secondary and tertiary branches of the mesenteric artery) is also activated independently of cGMP-PKG cascade by NO and/or NO donors (SIN-1, SNP) (Mistry and Garland, 1998) .
3) Inhibition of the formation of an endogenous MaxiK channel inhibitor 20-hydroxyeicosatetraenoic acid (20-HETE) Inhibition by NO of 20-HETE formation ( Fig. 3 (3) ) is also proposed as a mechanism by which NO activates MaxiK channel and causes blood vessel relaxation in a PKG-independent fashion Sun et al., 1998; . 20-HETE is a metabolite of arachidonic acid by cytochrome P450-dependent enzyme (CYP450 ω-hydroxylase, CYP450-4A2) (Fig. 8 ) that reduces MaxiK channel activity in rat renal arteriole smooth muscle cells (Zou et al., 1996) . Inhibition of 20-HETE formation by 17-octadecynoic acid (17-ODYA) activates MaxiK channel and this activation is counteracted by 20-HETE (Zou et al., 1996) . The signal transduction mechanism(s) by which 20-HETE inhibits MaxiK channel activity remains, however, unresolved. It might be plausible that tyrosine kinase(s) mediates the inhibitory effect of 20-HETE on MaxiK channel since its action is diminished by the inhibitors of this class of kinases (Sun et al., 1999) .
NO provided by NO donors (NONOate, SNP) inhibits the formation of 20-HETE through binding to heme of 20-HETE-producing enzyme CYP450-4A2 in renal arterioles (Sun et al., 1998) . In this vascular smooth muscle, NO activates MaxiK channel independently of cGMP-PKG cascade since SNP increases channel Po even under the condition where the cascade is inhibited with ODQ (a sGC inhibitor) or KT-5823 (a PKG inhibitor). Further, SNP-induced activation of MaxiK channel is prevented by 20-HETE whereas channel activity is enhanced with 17-ODYA (Sun et al., 1998) . These findings indicate that (1) 20-HETE inhibits MaxiK channel activity and inhibition of its formation leads to MaxiK channel activation; (2) NO-induced activation of MaxiK channel involves inhibition of 20-HETE formation. This mechanism seems to be also substantial in the dilation of cerebral artery in response to NO .
Prostaglandin I2 (PGI2, prostacyclin)
PGI2 is an eicosanoid of the cyclooxygenase pathway, which was first discovered by Vane's group (Moncada et al., 1976) . This prostanoid causes relaxation of smooth muscle in most vascular beds and inhibits platelet aggregation. However, for the purpose of its clinical use, stable PGI2 analogues (i.e., iloprost, cicaprost, beraprost) have been developed because the halflife of PGI2 itself is very short (<3 min). In vitro studies with isolated blood vessels show that PGI2 and its analogues cause relaxation in numerous vascular beds. For example, iloprost relaxes human pulmonary artery and vein (Haye-Legrand et al., 1987; Walch et al., 1999) , rabbit arteries (celiac, mesenteric, renal arteries) (Ercan and Turker, 1985) , guinea-pig aorta (Clapp et al., 1998; Ozaki et al., 1996) , and rat tail artery (Schubert et al., 1997) ; cicaprost relaxes human pulmonary artery and vein (Haye-Legrand et al., 1987; Walch et al., 1999) , guinea-pig aorta (Clapp et al., 1998) ; and beraprost relaxes dog arteries (cerebral, coronary, mesenteric, renal, femoral arteries) (Akiba et al., 1986) and guinea-pig aorta (Yamaki et al., 2001) .
1) Roles of cAMP and K + channels in PGI2-receptor (IPR)-mediated blood vessel relaxation
Biological actions of PGI2 and its analogues including relaxant effects on blood vessels are initiated when these chemicals activate a specific membrane-surface binding site (IP receptor, IPR) (Coleman et al., 1994; Narumiya et al., 1999) . IPR belongs to the G protein-coupled receptor (GPCR) family with seven transmembrane domains (Coleman et al., 1994; Narumiya et al., 1999; Wise and Jones, 1996) . Although several types of G-proteins are likely to be coupled with IPR, a key molecule is Gs, one of the functions of which is to activate adenylyl cyclase to elevate intracellular cAMP levels (Coleman et al., 1994; Narumiya et al., 1999; Wise and Jones, 1996) . The Gs-cAMP cascade has been proposed to be a major signaling system by which IP agonists elicit blood vessel relaxation. This view is supported by the evidence that IP agonists elevate tissue cAMP contents in several vascular beds and species: PGI2 in bovine coronary artery (Vegesna and Diamond, 1986) and rabbit aorta (Vegesna and Diamond, 1986) ; iloprost in human pulmonary artery (Clapp et al., 2002) and guinea-pig aorta (Ozaki et al., 1996; Turcato and Clapp, 1999) ; cicaprost in human pulmonary artery (Clapp et al., 2002) ; and beraprost in human pulmonary artery (Clapp et al., 2002) and in guinea-pig aorta (Yamaki et al., 2001) . This is also supported by our findings that prevention of cAMP degradation with a phosphodiesterase inhibitor potentiates beraprost-elicited relaxation (Yamaki et al., 2001) . Diminishment of iloprost-elicited vascular dilatation by PKA inhibitors (H-89, Rp-8-CPT-cAMPS) (Schubert et al., 1997 ) is additional evidence to support a substantial role of Gs-cAMP cascade in IPR-mediated blood vessel relaxation.
Another semi-final cellular event which may trigger IPR-mediated blood vessel relaxation is vascular smooth muscle membrane hyperpolarization. This view is supported by the evidence that PGI2/IP agonists cause membrane hyperpolarization of smooth muscle cells in intact blood vessel tissues: PGI2 in guinea-pig carotid artery (Corriu et al., 2001) ; and iloprost in dog carotid artery (Siegel et al., 1989a; 1989b) , guinea-pig coronary (Parkington et al., 1995) , carotid (Corriu et al., 2001) arteries, and rat middle cerebral artery (Lombard et al., 1999) . As in the case of NO-induced vascular responses, plasma membrane K + channel is a candidate protein class to generate membrane hyperpolarization of vascular smooth muscle cell upon stimulation of IPR (Siegel et al., 1989a; 1989b) . In this regard, two subclasses of K + channels have been proposed to elicit IPR-mediated membrane hyperpolarization and/or blood vessel relaxation. They are MaxiK channel (Table 1) and KATP channel. MaxiK channel roles were revealed by pharmacomechanical studies with iloprost in rat tail (Schubert et al., 1996; Schubert et al., 1997) and pulmonary arteries (Dumas et al., 1997) in guinea-pig aorta (Clapp et al., 1998) ; and with cicaprost (Clapp et al., 1998) and beraprost (Yamaki et al., 2001) in guinea-pig aorta. Iloprost increases MaxiK channel currents recorded in isolated arterial cells (Schubert et al., 1996; Schubert et al., 1997) . On the other hand, KATP channel roles are also supported by pharmacomechanical and electrophysiological studies using glibenclamide (KATP channel inhibitor) in rabbit coronary vessels (Jackson et al., 1993) ; guinea-pig coronary (Parkington et al., 1995) and carotid (Corriu et al., 2001) arteries; rat cerebral (Lombard et al., 1999) , pulmonary (Dumas et al., 1997) and tail (Schubert et al., 1997) arteries. Species-and tissue-specific roles for each subclass of K + channel remains to be resolved in IPR-mediated blood vessel responses.
2) MaxiK channel role in beraprost-elicited relaxation 2-1) Contribution of cAMP-dependent pathway By using beraprost (Akiba et al., 1986; Murata et al., 1989) as an IP agonist, we demonstrated that activation of MaxiK channel is the primary mechanism by which this IP agonist induces relaxation of guinea-pig aorta showing a functional coupling between MaxiK channel and IPR (Tanaka et al., 2004b; Yamaki et al., 2001 ). Contribution of cAMP-PKA cascade (cAMP-dependent pathway) to IPR-mediated MaxiK channel activation in guinea-pig aorta is significant as in studies with rat tail artery (Schubert et al., 1996; Schubert et al., 1997) because of the following lines of evidence: (1) beraprost elevates the tissue cAMP levels; (2) beraprostinduced relaxation is potentiated by Ro-20-1724 (a cAMP-specific phosphodiesterase inhibitor); (3) relaxation to 8-bromo-cAMP (a membrane permeable cAMP analogue) and the potentiated response to beraprost in the presence of Ro-20-1724 are strongly suppressed by IbTx (Yamaki et al., 2001) .
A mechanism by which cAMP-dependent pathway activates MaxiK channel and thus IPRmediated blood vessel relaxation is the channel phosphorylation by PKA (Schubert et al., 1996; Schubert et al., 1997) (Fig. 5 (1) ). Phosphorylation of MaxiK channel by PKA results in the apparent changes in voltage-and Ca 2+ -sensitivities of this ion channel (Schubert and Nelson, 2001 ) as in the case of PKG-mediated channel phosphorylation. Phosphorylation of MaxiK channel by PKA and its consequential channel activation are also demonstrated in some intact vascular and non-vascular smooth muscles (Kume et al., 1989; Meera et al., 1995; Sadoshima et al., 1988; Scornik et al., 1993; Zhou et al., 2000) . This mechanism partly accounts for MaxiK channel activation upon stimulation of β-adrenoceptor with its agonist, and is evidenced in: pregnant human and rat uterine myocytes (Zhou et al., 2000) ; pig coronary artery (Scornik et al., 1993) , ferret (Kume et al., 1994) and rabbit trachea (Kume et al., 1989) , rat aorta (Sadoshima et al., 1988) and guinea-pig cerebral artery (Song and Simard, 1995) . With regard to the coupling between β (β2)-adrenoceptor and MaxiK channel, these membrane proteins have been demonstrated to be coupled physically and functionally in smooth muscles including vascular smooth muscle (Liu et al., 2004) . Physical association of β2-adrenoceptor with the MaxiK channel α-subunit is attained through a PKA (PKAc)-anchoring protein (AKAP79/150), the presence of which is required for MaxiK channel regulation by a β2-adrenoceptor agonist. The PKA-anchoring protein also couples β2-adrenoceptor with L-type Ca 2+ channels (Cav1.2) (Liu et al., 2004) . High co-localization of β2-adrenoceptor with MaxiK channel enables a fast and efficient signaling transduction in sympathetic nervous system/hormonal regulation of smooth muscle membrane excitability and mechanical activity. Since IPR belongs to the Gs-protein coupled receptor like β-adrenoceptor, IPR might be also linked physically with the MaxiK channel. At the molecular level, possible channel phosphorylation site(s) for PKA exists in the MaxiK channel α-subunit (Toro et al., 1998) . Serine-869 in the C-terminal region can be one of the most significant phosphorylation residues for PKA to mediate β (β2)-adrenoceptor-MaxiK channel stimulatory coupling since this coupling is almost abolished by mutation of this residue in Xenopus oocytes co-expression system (Nara et al., 1998 ). An alternative PKA phosphorylation site of MaxiK channel is also present in the β (β1)-subunit (Toro et al., 1998) . However, it remains to be determined whether PKA-mediated channel alteration involves the modulation (phosphorylation) of this site. Other possible mechanisms by which cAMP-dependent pathway activates MaxiK channel are: PKA-triggered increase in Ca 2+ spark frequency through ryanodine-sensitive Ca 2+ release channels (Porter et al., 1998) ; and modulation by PKG via cAMP (Lincoln and Cornwell, 1993) 
2-2) Contribution of cAMP-independent pathway
Studies in the last decade indicate that cAMP-dependent pathway is not the exclusive signaling mechanism to underlie IPR-mediated blood vessel relaxation. Route(s) unrelated to the elevation in cAMP level has been demonstrated (cAMP-independent mechanism) (Turcato and Clapp, 1999; Yamaki et al., 2001 ) and this pathway(s) partly involve MaxiK channeltriggering (Yamaki et al., 2001 ). This view is supported by the following lines of evidence: (1) beraprost-induced relaxation is not affected by an adenylyl cyclase inhibitor SQ 22,536 whereas elevation of smooth muscle cAMP contents by beraprost is abolished by SQ 22,536; and (2) the cAMP-independent component of beraprost-elicited relaxation generated in the presence of SQ 22,536 is suppressed significantly by IbTx (Yamaki et al., 2001 ). The latter is direct evidence that MaxiK channel plays a key role in IPR-mediated, cAMP-independent blood vessel relaxation. With regard to the molecular mechanisms by which cAMP-independent pathway activates MaxiK channel, at least two signaling cascades seem to be possible to explain the channel modulatory process: i) "ligand modulation", and ii) "G-protein gating" (Tanaka et al., 2004b; . Ligand modulation-Ligand modulation means "direct effect of chemical stimulants on the MaxiK channel pore-forming α-subunit to induce channel gating alteration" . Ligand modulation also includes the channel modulation resulting from the binding of chemical stimulants to MaxiK channel-associated molecules in the channel vicinity such as the β-subunit, or associated receptor . The view on this type of channel modulation was originally proposed for the stimulatory effects of arachidonic acid on native MaxiK channel in pig coronary artery (Toro and Scornik, 1991) . Similar mechanism to enhance MaxiK channel activity by arachidonic acid was also found to be present in rabbit pulmonary artery (Kirber et al., 1992) and coronary artery (Ahn et al., 1994) . Arachidonic acid also activates MaxiK channel α-subunit (hslo) possibly through a direct 2 mechanism (Fig. 6 ). However, in the case of IPR-mediated activation of MaxiK channel, this possibility seems marginal since beraprost does not affect channel currents flowing through the intact smooth muscle MaxiK channel in the absence of GTP and those through MaxiK α-subunit/MaxiK α+β1-subunit channels transiently expressed in Xenopus oocytes (our unpublished observations). G-protein gating-The concept of "G-protein gating", proposed first for acetylcholineactivated K + channel in cardiac (atrial) cells (Brown and Birnbaumer, 1990) means that a chemical receptor-coupled G-protein alters ion channel gating properties through a direct interaction with the targeted ion channel (Toro, 1995) ( Fig. 5 (2) ). In vascular smooth muscle, the direct modulation of MaxiK channel by G-protein (Gs) was first demonstrated in coronary smooth muscle for β-adrenoceptor stimulation (Scornik et al., 1993) ; this view was clearly supported by the following: (1) GTP-γS applied to the cytoplasmic surface of MaxiK channel activates reconstituted channel even in the presence of a PKA inhibitor (PKI); and (2) the 2 It could be also possible that arachidonic acid activates MaxiK channel through mediation of G-proteins as in the case of EET, which is addressed in EDHF section. If this is the case, the usage of "direct" may not be appropriate.
activated Gs (Gα*s) enhances MaxiK channel activity whilst βγ-subunits do not affect MaxiK channel activity (Scornik et al., 1993) . In this case, a molecular candidate to activate MaxiK through phosphorylation-unrelated mechanisms is β-adrenoceptor-coupled Gs. The same mechanism also works for uterine (Toro et al., 1990) and tracheal smooth muscle MaxiK channel (Kume et al., 1994) . The channel direct modulation by Gs-protein accounts in part for cAMP-independent activation of MaxiK in IPR-mediated blood vessel responses because of the following lines of evidence: (1) GTP (100 µM), which is applied to the cytoplasmic surface of MaxiK channel recorded in inside-out patches, increases MaxiK Po if IPR is stimulated with beraprost from the external side of the patch membrane (Fig. 7) ; (2) GTPγS (100 µM) applied to the cytoplasmic surface of MaxiK channel increases MaxiK Po under the condition that IPR is not stimulated with beraprost; (3) cholera toxin (CTX) (1 µg/mL), an activator of Gs, increases MaxiK channel Po to a similar extent that is attained with GTP plus beraprost or GTPγS alone; (4) relaxant effects of CTX on guinea-pig aorta in the presence of SQ 22,536 (100 µM) are attenuated partly by IbTx. These findings provide evidence for a direct functional coupling of MaxiK channel with Gs in this vascular smooth muscle (Tanaka et al., 2004b; Yamaki et al., 2001 ). This mechanism is also substantial in β2-adrenoceptor-mediated relaxation of tracheal smooth muscle (Tanaka et al., 2003a; 2003b) . 
EDHF
Endothelium-derived hyperpolarizing factor (EDHF) (Busse et al., 2002; Garland et al., 1995; McGuire et al., 2001; Mombouli and Vanhoutte, 1997; Quilley and McGiff, 2000; Suzuki et al., 1992; Suzuki, 2003; Suzuki et al., 1998; Taylor and Weston, 1988) was originally defined as "non-EDRF (NO), non-PGI2 endothelium-derived substance that activates K + channels" (Suzuki, 2003) . Since then, the concept of EDHF has been changing and EDHF seems to be now extensively interpreted as "the endothelium-derived non-NO-and non-PGI2 substance, the relaxant effect of which is diminished in high K + solution" (Suzuki, 2003) . The physiological significance of EDHF as well as its chemical identity(ies) still remains elusive. However, it is widely approved that the contribution of EDHF is superior to that of NO in small resistance arteries (Busse et al., 2002; McGuire et al., 2001; Suzuki et al., 1998) , which suggests that EDHF serves as an indispensable determinant in controlling microvessel resistance. EDHF might also function as a backup system to compensate for NO deficiency (Najibi et al., 1994) .
Pharmacological profiles of EDHF greatly vary according to species, vascular beds and possibly the agonists used. This may be one of the reasons why EDHF is not yet chemically identified as a universal diffusible chemical factor though some EDHF candidates have been proposed so far. EDHF candidates are: L-citrulline (Ruiz and Tejerina, 1998) , K + ion itself (Edwards et al., 1998) , H2O2 (Matoba et al., 2000) , an endogenous cannabinoid (anandamide) (Randall et al., 1996; Randall and Kendall, 1998) and epoxyeicosatrienoic acids (EETs) including 11,12-EET synthesized by CYP450 (Archer et al., 2003; Campbell et al., 1996; Popp et al., 1996; Quilley and McGiff, 2000) . However, none of these EDHF candidates can universally explain non-NO, non-PGI2-mediated membrane hyperpolarization and blood vessel relaxation over species-and regional-diversities. An alternative explanation for non-NO-, non-PGI2-mediated endothelium-dependent membrane hyperpolarization and vascular relaxation is that the responses are not mediated via a diffusible factor, but are elicited by an electrotonic propagation from the endothelium to vascular smooth muscle via heterocellular myo-endothelial gap junctions 3 , which provide a low-resistance electrical pathway between these cell layers (Suzuki, 2003; Yamamoto et al., 1998) . K + channels in vascular smooth muscle are the prevailing target for EDHF as for NO and PGI2; the hyperpolarization of smooth muscle plasmalemma is attributed to the opening of a K + channel but not due to the closing of a Cl -channel or a non-specific cationic channel. However, the subclass of vascular smooth muscle K + channels responsible for EDHF-mediated response remains inconclusive. The most well-known pharmacological profile that is approved as a hallmark of the EDHF-mediated response is that it is abolished by the combination of apamin (a specific SKCa channel inhibitor) and ChTx (a MaxiK channel inhibitor that also inhibits intermediate Ca 2+ -activated K + (IKCa) channel and some Kv channels). However, targets for the combination of apamin and ChTx seem to be two subclasses of KCa channels (SKCa and IKCa channels) expressed on endothelial cells (Busse et al., 2002; Edwards et al., 1998) However, in some blood vessels, MaxiK channel in the vascular smooth muscle might serve as a target for EDHF itself (Popp et al., 1996) and/or EDHF candidate, EETs (Archer et al., 2003; Campbell et al., 1996; Li and Campbell, 1997a; Li et al., 1997b; Roman et al., 2000) . EETs (e.g., 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET) are CYP450 mono-oxygenase (epoxygenase) metabolites of arachidonic acid (Fig. 8) and are produced/released from the endothelium upon stimulation with neurohumoural substances including ACh and bradykinin. This mechanism has been proposed in bovine coronary artery (Campbell et al., 1996) and human mammary artery (Archer et al., 2003) where: (1) EETs produce an endothelium-independent vascular relaxation; (2) EETs produce a membrane hyperpolarization of vascular smooth muscle.
Supporting a role of EETs in porcine coronary artery, β-naphthoflavone-mediated 11,12-EET production is accompanied by an increase of EDHF-mediated hyperpolarization and relaxation which can be downregulated with CYP450-2C8/34 antisense oligonucleotides (Fisslthaler et al., 1999) . The view that MaxiK channel is a target for EETs is supported by the following lines of evidence 4 (Table 1) : (1) Endothelium-dependent, non-NO, non-PGI2-mediated relaxation induced by arachidonic acid, which is sensitive to a CYP450 inhibitor, is attenuated by ChTx (Miura and Gutterman, 1998) ; (2) bradykinin-produced EDHF activates MaxiK channel (Popp et al., 1996) ; (3) the relaxation induced by EETs is attenuated by TEA, ChTx (Campbell et al., 1996) or IbTx (Archer et al., 2003) ; (4) EETs increase vascular smooth muscle MaxiK channel Po: 11,12-EET (Archer et al., 2003; Campbell et al., 1996; Li and Campbell, 1997a; Li et al., 1997b ), 14,15-EET (Campbell et al., 1996 ; (5) membrane hyperpolarization by 11,12-EET is diminished by IbTx (Archer et al., 2003) . However, 11,12-EET is not the EDHF mediating non-NO, non-PGI2 responses generated in other blood vessels such as rat hepatic and mesenteric arteries (Edwards et al., 1998; Zygmunt et al., 1996) and guinea-pig coronary artery (Eckman et al., 1998) . Molecular mechanisms by which EETs enhance the MaxiK channel activity were explored CYP450 epoxygenases oxidize arachidonic acid to generate four regioisomer cisEETs: 14, 15-EET, 11, 12-EET, 8, 9-EET, 5, 6-EET. Each regioisomer consists of RS and/or SR optical antipode. Although multiple CYP450 epoxygenase isoforms are expressed in vascular endothelium, CYP450-2C8/34 was identified as an EDHF synthase to mediate the formation of 11, 12-EET in native porcine coronary artery endothelial cells (Fisslthaler et al., 1999) . In human endothelial cells CYP450-2J2 isoform was identified as an EDHF synthase (Node et al., 1999) . Each EET is further converted to its corresponding diol (dihydroxyeicosatrienoic acid, DHET). Also shown is the arachidonic acid conversion to hydroxyeicosatetraenoic acid (20-HETE) catalysed by ω-hydroxylase.
and the direct effect on the channel through Gsα has been proposed (Li and Campbell, 1997a ).
This view is evidenced by the finding that: (1) enhancement by 11,12-EET of MaxiK activity recorded in the inside-out excised patch membrane requires GTP in the internal side of the channel whilst 11,12-EET activates MaxiK in cell-attached configurations; (2) GTP-dependent MaxiK channel activation by 11,12-EET is inhibited by GDP-βS; (3) 11,12-EET-elicited enhancement of MaxiK activity is blocked by a specific anti-Gsα antibody but not by anti-Gβγ or anti-Giα antibody; (4) activation of MaxiK channel is also elicited by cholera toxin. Later, Li et al. (Li et al., 1999) showed a role for endogenous mono-ADP-ribosyltransferases in 11,12-EETinduced vascular response suggesting that the ADP-ribosylation of Gsα triggers the activation of MaxiK channel by 11,12-EET. This mechanism seems to be elicited without the requirement of MaxiK channel β1-subunit (Fukao et al., 2001) .
Conclusion
In this review article, we summarized and discussed blood vessel MaxiK channel roles as a key element to integrate and communicate the chemical signaling generated in the endothelium to the underlying vascular smooth muscle to control the mechanical functions of blood vessels. This idea was first raised based on the findings by electrophysiologists that MaxiK channel transduces the effects of NO through a PKG-mediated channel phosphorylation, which subsequently attracted the attention of many pharmacologists. The detailed molecular mechanisms by which NO-cGMP system activates MaxiK channel are still under scrutiny. Besides NO-cGMP cascade, MaxiK channel significantly contributes to blood vessel relaxation induced by PGI2, and to EDHF-mediated relaxation in some blood vessels. In both cases, MaxiK channel seems to be activated in part through direct regulation of this channel by Gs. Furthermore, MaxiK channel is a target for endothelium-derived vasoconstrictors such as thromboxane A2 (TXA2) (Scornik and Toro, 1992) and endothelin (Hu et al., 1991) , and this K + channel might play a role in the blood vessel constrictions induced by these chemicals. In summary, vascular smooth muscle MaxiK channel serves as a key element that functionally couples chemical signals generated in the endothelium with changes in blood vessel electrical and mechanical activities to control circulatory systems and thus physiological functions of each organ. 
